ocriplasmin
Selected indexed studies
- Ocriplasmin for symptomatic vitreomacular adhesion. (Cochrane Database Syst Rev, 2017) [PMID:29040800]
- Ocriplasmin: who is the best candidate? (Clin Ophthalmol, 2016) [PMID:27051270]
- Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials. (Surv Ophthalmol, 2022) [PMID:34480895]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ocriplasmin for symptomatic vitreomacular adhesion. (2017) pubmed
- Ocriplasmin: who is the best candidate? (2016) pubmed
- Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials. (2022) pubmed
- Ocriplasmin for Treatment of Vitreomacular Traction: An Update. (2016) pubmed
- Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion. (2014) pubmed
- Ocriplasmin for diabetic retinopathy. (2013) pubmed
- Ocriplasmin for vitreomacular traction. (2016) pubmed
- Ocriplasmin for vitreoretinal diseases. (2012) pubmed
- Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications. (2016) pubmed
- Intravitreal ocriplasmin: A breakthrough in the treatment of vitreomacular traction? (2017) pubmed